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To maximize benefits and reduce potential harms of organized cancer screening programs in Europe, 
monitoring, quality assurance and evaluation of the long-term impact are required. We aimed to identify 
the most important indicators that are required to collect and report. The study was designed to establish 
a consensus within a European-level working group and come up with a manageable list of key indicators. 
We conducted a Delphi study among policymakers, researchers and program coordinators who were 
experts in breast, cervical or colorectal cancer screening. Study participants evaluated the importance of 
screening indicators on a 5-point Likert-scale. Interval cancer rate, detection rate, screening attendance, 
screening coverage, cancer incidence, cause-specific mortality, proportion of persons attending further 
assessment after a positive screen test result, proportion of persons attending a treatment after 
diagnosis, invitation coverage, and distribution of cancers by mode of detection were the top 10 indicators 
by study participants. In general, performance indicators were considered more important than outcome 
indicators. Sub-group analyses by cancer types showed similar results and only experts of cervical cancer 
screening had slightly different preferences. Sub-group analyses by experts’ roles indicated that 
policymakers found different indicators important compared to researchers or program coordinators, 
probably because of their different point of view on screening. The implication of our priority ranking is 
twofold: it serves as an initial guidance for countries that have not yet established a system to collect 
data; and as a checklist for those where data collection is already established to assess the 
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The Council of the European Union (EU) recommended in 2003 that screening for breast, cervical and 
colorectal cancer should take place only in a form of organized, population-based programs. It also 
specified the fundamental principles of early detection of cancer and presented a shared commitment by 
Member States to implement organized screening programs [1]. The 4th Edition of the European Code 
against Cancer states that organized screening programs are preferred to opportunistic screening as these 
provide better conditions for quality assurance to achieve the greatest benefit with the least harm [2]. 
However, there is still a need for better monitoring, quality assurance and evaluation of the long-term 
impact of organized cancer screening in Europe [3,4,5]. Quality assurance and continuous evaluation are 
among the key principles of implementing screening programs [6] and the programs’ effectiveness highly 
depends on these procedures [7]. Still, a study conducted among European countries showed that efforts 
for these activities are carried out to a differing and non-standardized extent, which makes it difficult to 
compare long-term effects of screening programs [8]. 
There have been several attempts to provide guidance on collecting data for quality assurance and 
monitoring screening programs. Indicators on quality and performance have already been defined by the 
European quality assurance guidelines for breast, cervical and colorectal cancer [9,10,11,12,13]. These 
provide an overview of the fundamental points and principles that supports quality assurance and 
identifies performance indicators to collect. The second report on Cancer Screening in the EU published in 
2017, aims to provide the most up-to-date information on the implementation of Council 
recommendations [14]. In this report, over 80 experts from EU member states provided data on the 
implementation status and on the performance indicators for breast, cervical and colorectal cancer 
screening [14]. Similarly to the first report on Cancer Screening in the EU [15], it also provided justification 
for initiatives at European level and in the member states to expand and improve implementation of 
population-based programs. It also revealed that the data collection for more complex performance 
indicators was limited in several countries due to the lack of continuous and systematic evaluation in 
place. Several other EU initiatives also generated knowledge and evidence for measuring and evaluating 
the performance of screening programs such as the EUROCOURSE [16], the EUNICE [17] and the 
EUROSCREEN [18]. 
These previous initiatives recommend to collect many indicators including more complex ones for 
monitoring quality and performance. However, some countries with less of a tradition or experience in 
screening and with fewer resources or without up-to-date registries are unlikely to collect them all. This 
makes European level comparison on the effect of different programs more challenging. Therefore, a key 
list of indicators is needed which is relatively short and developed by a consensus among European 
experts. This study aimed to identify the most important indicators to collect for measuring the impact of 
organized screening programs. We also investigated the key indicators across different cancer types and 
took into account different roles of experts in the screening programs.  
This study was conducted within the EU-TOPIA (Towards improved screening for breast, cervical and 
colorectal cancer in all of Europe) H2020 project that aims to systematically evaluate and quantify the 
harms and benefits of screening programs for breast, cervical, and colorectal cancer in all European 
countries1. It also intends to build capacity for future self‐evaluation of screening programs in Europe, for 
which providing a list of key indicators is important.  
                                                          





We developed a set of key indicators to monitor the effects of screening programs in a Delphi study with 
the involvement of screening experts from Europe who participated at the EU-TOPIA workshop about 
screening indicators in September 2017 in Budapest, Hungary2. Participants were either researchers, 
screening program coordinators or policymakers related to breast, cervical or colorectal cancer screening 
programs. Experts were asked to specify their role(s) in the screening program and the cancer site(s) of 
their expertise. All participants were allowed to select more than one role and more than one cancer site. 
The Delphi process was carried out according to the steps described in the literature [19,20] with the 
adaptations detailed below. The current study consisted of three consecutive rounds.  
Round 1 was a preparatory phase, where a literature review was carried out to identify an extensive pool 
of indicators for evaluating organized cancer screening programs.3 In Delphi studies it is both an 
acceptable and a common modification to use a structured questionnaire, which is based on a literature 
review in Round 1 [20]. Based on the review 27 indicators that can be used to estimate the long-term 
effectiveness of cancer screening programs were defined for this study (Table 1).  
In Round 2, a 27-item online questionnaire was sent to EU-TOPIA workshop participants in advance. 
Participants had to individually evaluate the importance of each listed indicator on a 5-point Likert-scale. 
The following values were attributed to the scale: strongly disagree: -2; disagree: -1; neutral: 0; agree: 1; 
strongly agree: 2. Round 2 was completed in August-September 2017. After the data collection, a 
summary of Round 2 was sent to participants showing aggregated results for each indicator, which were 
presented on a bar chart showing the frequency of each option on the scale.  
In Round 3, results of Round 2 were presented at the EU-TOPIA workshop and discussed by a roundtable 
panel, which gave all study participants in the audience an opportunity to refine their opinion before final 
voting round. A mobile phone application was used for voting at the workshop. Participants were also 
asked whether they filled in the online survey in Round 2. Therefore, a sub-group of Round 3 answers was 
possible to be analysed among those who participated in both rounds. 
To develop the priority list, indicators were ranked according to the mean value of survey answers. 
Indicators, which many participants strongly supported had high mean value because of the 
abovementioned coding of answers. The symmetrical values on the scale ensured that “strongly disagree” 
has the same negative weight as positive weight “strongly agree” had. This holds for the categories of 
“disagree” and “agree”, as well. To characterize the level of consensus related to each indicator a 
previously published consensus measurement was used [21,22]. This measure is typically applied to the 
Likert-scale to determine degrees of agreement among ordinal-ranked categories. The value of consensus 
ranges from 0 to 1, the latter meaning perfect consensus. If two indicators had the same mean value, then 
the one with larger consensus measure score got higher rank on the list. In the current paper the top 10 
indicators from the full list are considered as key indicators.  
 
<Table 1 about here>
                                                          
2 http://eu-topia.org/workshops/workshop-1-monitoring/  




A total of 143 and 73 respondents filled in the survey in Round 2 and Round 3, respectively. For the 
further analysis only those who completed all questions were included, resulting in 89 and 61 participants, 
respectively. Respondents represented 31 European countries. In Round 2 none of the listed indicators 
had a negative mean value, while in Round 3 one indicator had a mean value below 0, indicating the 
lowest importance (Table 1).  
The list of top 10 indicators for Round 3 was identical to Round 2 (hereafter TOP10), only the order of the 
indicators changed (Table 2). The TOP10 indicators were interval cancer rate, detection rate, screening 
attendance, screening coverage, cancer incidence, cause-specific mortality, proportion of persons 
attending a further assessment after positive screen test result, proportion of persons attending a 
treatment after diagnosis, invitation coverage, and distribution of cancers by mode of detection. Results 
also show that indicators measuring the performance of the screening programs (e.g. interval cancer rate, 
detection rate, screening attendance or coverage) were graded higher than indicators measuring the 
outcomes of the programs (e.g. cause specific mortality).  
In Round 2 there was a relatively minor difference between the 10th and the 11th ranked indicators (mean 
scores 1.247 vs. 1.236, respectively) but a larger difference was observed in Round 3 (mean scores 1.262 
vs. 1.066, respectively) (Table 1). The average consensus score considering all indicators also increased in 
Round 3 (0.711) compared to Round 2 (0.701).  
The first sub-group analysis was conducted among Round 3 participants who also filled in the Round 2 
online survey (n=49). The list of top 10 indicators in this sub-group was also identical to the TOP10, only 
the order was different (Table 2). Similarly to the overall results of Round 3, we observed a relatively large 
difference between the 10th and the 11th ranked indicators (mean scores 1.265 vs. 1.061, respectively). 
The average consensus score considering all indicators was similar (0.710) to the overall result of Round 3 
(0.711). 
<Table 2 about here> 
The second sub-group analysis was conducted according to the participants’ fields of expertise (breast, 
cervical or colorectal). Of the workshop participants, 42 indicated breast, 29 indicated cervical and 33 
colorectal cancer as a field of expertise. The top 10 indicators were identical across breast and colorectal 
cancer experts, only the order was different (Table 3). Their list was also identical with the TOP10. Cervical 
cancer experts included two indicators which were not included for breast and colorectal expects (namely, 
complications related to the screening test; and complications related to referral examinations). The two 
indicators replaced by these items were invitation coverage, and compliance with treatment (marked in 
Table 3 with hyphen).  
<Table 3 about here> 
The third sub-group analysis was conducted according to the participants’ roles in cancer screening 
programs. Of the workshop participants 36 indicated researcher, 29 program coordinator and 10 
policymaker role. The top 10 indicators were identical for researchers and program coordinators, only the 
order was different (Table 4). Their list was also identical with the TOP10. Policymakers included five 
indicators, which were not included by researchers and program coordinators (proportion of persons 
falsely referred for further assessment; complications related to the screening test; complications related 
 
to referral examinations; proportion of cancer patients treated with any treatment; probability that a 
person with a positive screen test result has cancer (Table 4).  
 




Despite the considerable progress on the implementation and organization of cancer screening programs 
in the EU member states since 2003, much work remains to be done and procedures for continued 
monitoring, regular feedback and periodic reporting should be ensured [23]. Our study adds to this 
recommendation by providing a consensus of screening experts on the most important indicators that are 
required to evaluate organized screening programs. Previous initiatives monitoring and quality assurance 
have not attempted to prioritize among organized screening program indicators.  
We found a strong consensus among European screening experts on the key indicators of organized 
screening programs. In the third round of the Delphi panel we observed a larger difference between the 
10th and the 11th ranked indicators compared to the previous round and also we observed an increase in 
the average consensus value. This indicates that workshop participants had a better consensus during the 
face-to-face meeting towards defining a list of key indicators.  
Screening experts had a strong consensus that interval cancer rate, screening attendance, screening 
coverage are the most important indicators of screening programs. Interestingly, they ranked 
performance indicators higher than outcome indicators, probably due to the closer temporal and causal 
association of screening efforts with performance indicators than with outcome indicators. On the other 
hand, as effective mobilization of the population, good organization of the screening programs and good 
quality of the screening tests are all prerequisites of health benefits, thus this ranking is not that 
surprising. 
Although indicators on screening benefits were generally graded with higher priority, indicators on 
potential harms should not be neglected. There is still an ongoing debate over the benefits and harms of 
screening programs [24]. Therefore, when countries evaluate their programs data collection should 
include for instance overdiagnosis since it causes overestimations of the sensitivity, specificity, and 
positive predictive value of screening tests and the incidence of disease [25]. 
Sub-group analyses by cancer sites and roles in the screening program showed similar results, except for 
experts in cervical cancer and for policymakers. Experts in cervical cancer ranked indicators on 
complications related to the screening test and to referral examinations higher compared to the other two 
cancer sites. This indicates that the quality assurance of these examinations and monitoring of side effects 
should be prioritized even though complications for the cervical screening itself is low and it can be 
conducted safely even by trained health visitors [26].  
We also found that policymakers in general have different priorities compared to other stakeholders, 
which may have different reasons. First, our sample size (n=10) was low compared to researchers (n=36) 
and program coordinators (n=29). Therefore, data on policymakers were less robust to define the top 10 
indicators. Second, policymakers tended to put more emphasis on the potential harms of screening 
activities (i.e. proportion of persons falsely referred for further assessment; complications related to the 
screening test; complications related to referral examinations) since these are politically more sensitive 
issues. In general, they seem to prioritize the close monitoring of these undesired events that could place 
screening into a negative context. However, these data are often not routinely available from the 
screening databases. 
The other two stakeholder groups had the same top 10 indicators, but the individual rankings of the 
indicators were somewhat different. Most notably cause-specific mortality was ranked as the second most 
important indicator for researchers and it was only the 7th most important for program coordinators. 
 
Giving higher priority to performance indicators (e.g. detection rate, interval cancer rate, screening 
coverage or screening attendance) was even more noticeable in case of program coordinators compared 
to the other two stakeholder groups. We do believe, that this is because these indicators are more closely 
relate to their responsibilities in the screening programs.  
It is important to note that due to the specific approach of early detection with screening, the evaluation 
of long-term outcomes is not feasible for many years after program implementation. Still, indicators on 
the impact of screening should be closely and systematically monitored to give an early indication of 
whether the program could lead to the expected benefits. Based on this approach, health economic 
modeling could be applied to estimate long-term outcomes and the cost-effectiveness of a program, 
which has been illustrated in previous examples with even considerable influence on screening policy 
[27,28,29,30]. 
This study has some limitations due to its design. First, Delphi studies are usually carried out in a smaller 
number of experts from the same field. However, representation should be assessed by the qualities of 
the expert panel rather than its numbers [31]. Since we aimed to achieve a consensus among European 
screening experts our sample size included experts in three cancer sites from relevant institutes of cancer 
screening throughout 31 European countries. Second, although we attempted to cover as wide range of 
indicators as possible we had to limit these to a manageable list in order to perform the Delphi exercise. 
Therefore, there might be some aspects of organized screening programs that were not captured in the 
analysis. Nonetheless, our initial list is based on a comprehensive review of the literature which was made 
publicly available by the EU-TOPIA project before the study.  
Our study did not cover practical and feasibility issues of data collection or timely availability of relevant 
data. These issues however, should be handled by individual countries, according to their institutional 
settings (e.g. national registries, screening coordination organizations), legal environment on personal 
data (e.g. data linkage between organizations) and screening related know-how. Another issue might be 
the definition of more complex indicators such as the interval cancer [32]. Therefore, further efforts for 




This study was the first that attempted to provide a small set of key indicators in over three different 
cancer sites by relying on the opinion experts. We found a strong consensus among European screening 
experts on the key list of screening indicators. Sub-group analyses revealed some differences, more 
notably for policymakers who had slightly different perspective. The implication of our priority ranking 
depends on the countries’ current practice of systematic data collection and regular monitoring. We 
recommend that countries without regular and systematic approach of monitoring should primarily design 
their system to collect at least the defined key indicators. Countries where a systematic approach for data 
collection is already in place, our priority ranking should be considered as a checklist by which monitoring 
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Table 1: Mean scores and consensus values for Round 2 and Round 3 








in Round 2 
Consensus 
in Round 3 
1) The age distribution of the population. 0.865 0.590 0.641 0.647 
2) The life-expectancy of population. 0.775 0.311 0.641 0.624 
3) The number of newly diagnosed cancer cases (i.e. incidence) in a population. 1.303 1.508 0.730 0.776 
4) The proportion of cancer patients treated with any treatment. 0.573 1.033 0.624 0.761 
5) The (cumulative) relative survival of cancer patients in a given time frame. 0.910 0.426 0.632 0.555 
6) The number of deaths from the given cancer (i.e. cause-specific mortality) in a population. 1.393 1.574 0.699 0.790 
7) The proportion of screening tests outside organized screening (i.e. opportunistic screening). 0.820 0.672 0.706 0.686 
8) The proportion of complications related to the screening test. 0.978 0.951 0.654 0.628 
9) The proportion of complications related to the referral examinations. 0.933 0.885 0.662 0.655 
10) The proportion of complications related to primary treatment for a screen detected disease. 0.551 0.574 0.637 0.627 
11) The age range of persons targeted to screening. 1.101 0.885 0.691 0.668 
12) The time between regular invitations (i.e. screening interval). 0.933 0.738 0.697 0.664 
13) The proportion of persons invited at least once in a given time frame (i.e. invitation coverage). 1.247 1.328 0.732 0.693 
14) The proportion of persons examined at least once in a given time frame (i.e. screening coverage). 1.348 1.574 0.691 0.725 
15) The proportion of persons invited or examined at least once in a given time frame (i.e. service provider 
coverage). 
0.876 0.787 0.702 0.702 
16) The proportion of persons examined in a given time frame (i.e. screening attendance). 1.438 1.525 0.754 0.750 
17) The proportion of different test results (for example 'positive', 'negative' or 'inadequate'). 1.157 0.902 0.754 0.675 
18) The proportion of persons attending a further assessment after a positive screen test result. 1.326 1.443 0.733 0.725 
19) The proportion of persons attending a treatment after a diagnosis. 1.303 1.344 0.765 0.708 
20) The distribution of histological diagnosis (pre-cancers and cancers) (i.e. detection rate). 1.404 1.639 0.727 0.809 
21) The distribution of cancers by the mode of detection (for example, 'pre-screening', 'screen-detected', 'interval 1.348 1.262 0.732 0.701 
 
cancer in participant', 'cancer in non-participant', 'post-screening'). 
22) The number of newly diagnosed cancer cases after a negative screening episode (i.e. a negative primary test, 
or negative follow-up after a positive primary test) in a population (i.e. interval cancer rate). 
1.371 1.639 0.738 0.785 
23) The proportion of screen attenders with at least one biopsy. 0.326 -0.180 0.670 0.752 
24) Episode sensitivity. 1.236 1.000 0.769 0.848 
25) The proportion of true negative test results in people without cancer (i.e. test specificity). 1.213 1.049 0.731 0.739 
26) The probability that a person with a positive screen test result has cancer (or a pre-invasive stage) (i.e. 
positive predicted value). 
1.180 1.066 0.735 0.767 
27) The proportion of persons falsely referred for further assessment (i.e. false positive rate). 0.955 0.951 0.678 0.729 







Rank in Round 3 
(participants in 
both rounds) 
The number of newly diagnosed cancer cases after a negative 
screening episode (i.e. a negative primary test, or negative 
follow-up after a positive primary test) in a population (i.e. 
interval cancer rate). 
4 2 1 
The distribution of histological diagnosis (pre-cancers and 
cancers) (i.e. detection rate). 
2 1 2 
The proportion of persons examined in a given time frame (i.e. 
screening attendance). 
1 5 3 
The proportion of persons examined at least once in a given time 
frame (i.e. screening coverage). 
6 4 4 
The number of newly diagnosed cancer cases (i.e. incidence) in a 
population. 
9 6 5 
The number of deaths from the given cancer (i.e. cause-specific 
mortality) in a population. 
3 3 6 
The proportion of persons attending a further assessment after a 
positive screen test result. 
7 7 7 
The proportion of persons attending a treatment after a 
diagnosis. 
8 8 8 
The proportion of persons invited at least once in a given time 
frame (i.e. invitation coverage). 
10 9 9 
The distribution of cancers by the mode of detection (for 
example, 'pre-screening', 'screen-detected', 'interval cancer in 
participant', 'cancer in non-participant', 'post-screening'. 















The number of newly diagnosed cancer cases after a negative 
screening episode (i.e. a negative primary test, or negative 
follow-up after a positive primary test) in a population (i.e. 
interval cancer rate). 
2 1 1 1-2* 
The distribution of histological diagnosis (pre-cancers and 
cancers) (i.e. detection rate). 
1 2 2 1-2* 
The number of deaths from the given cancer (i.e. cause-specific 
mortality) in a population. 
3 3 4 6 
The proportion of persons examined in a given time frame (i.e. 
screening attendance). 
5 4 7 5 
The proportion of persons examined at least once in a given 
time frame (i.e. screening coverage). 
4 5 5 3 
The proportion of persons attending a further assessment after 
a positive screen test result. 
7 6 6 7 
The number of newly diagnosed cancer cases (i.e. incidence) in 
a population. 
6 7 3 4 
The proportion of persons invited at least once in a given time 
frame (i.e. invitation coverage). 
9 8 - 8 
The proportion of persons attending a treatment after a 
diagnosis. 
8 9 - 9 
The distribution of cancers by the mode of detection (for 
example, 'pre-screening', 'screen-detected', 'interval cancer in 
participant', 'cancer in non-participant', 'post-screening'). 
10 10 8 10 
The proportion of complications related to the referral 
examinations. 
- - 9 - 
The proportion of complications related to the screening test. - - 10 - 

















The number of newly diagnosed cancer cases after a 
negative screening episode (i.e. a negative primary test, or 
negative follow-up after a positive primary test) in a 
population (i.e. interval cancer rate). 
2 1 2 4 
The number of deaths from the given cancer (i.e. cause-
specific mortality) in a population. 
3 2 7 1 
The distribution of histological diagnosis (pre-cancers and 
cancers) (i.e. detection rate). 
1 3 1 3 
The number of newly diagnosed cancer cases (i.e. 
incidence) in a population. 
6 4 5 2 
The proportion of persons examined at least once in a 
given time frame (i.e. screening coverage). 
4 5 3 - 
The proportion of persons attending a further assessment 
after a positive screen test result. 
7 6 6 9 
The proportion of persons examined in a given time frame 
(i.e. screening attendance). 
5 7 4 - 
The distribution of cancers by the mode of detection (for 
example, 'pre-screening', 'screen-detected', 'interval 
cancer in participant', 'cancer in non-participant', 'post-
screening'). 
10 8 9 - 
The proportion of persons invited at least once in a given 
time frame (i.e. invitation coverage). 
9 9 10 8 
The proportion of persons attending a treatment after a 
diagnosis. 
8 10 8 - 
The proportion of persons falsely referred for further 
assessment (i.e. false positive rate). 
- - - 5 
The proportion of complications related to the screening 
test. 
- - - 6 
The proportion of complications related to the referral 
examinations. 
- - - 7 
The proportion of cancer patients treated with any 
treatment. 
- - - 10-11* 
The probability that a person with a positive screen test 
result has cancer (or a pre-invasive stage) (i.e. positive 
predicted value). 
- - - 10-11* 
*The mean value and the consensus value was the same for these indicators 
